NP-12 (Synonyms: AUR-012, SNTSESFK(SNTSESF)FRVTQLAPKAQIKE-NH2) |
| رقم الكتالوجGC36767 |
NP-12 (NP-12) هو مضاد ببتيد لمسار إشارات PD-1 ، ويعرض عداءًا متساويًا تجاه PD-L1 و PD-L2 في إنقاذ تكاثر الخلايا الليمفاوية ووظائف المستجيب. يُظهر NP-12 تنشيطًا مناعيًا ونشاطًا ممتازًا مضادًا للأورام وإمكانية إدارة أفضل للأحداث الضائرة المرتبطة بالمناعة (irAEs).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1353563-85-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NP-12 is a peptide antagonist of the PD-1 signaling pathway, which acts as an immunomodulatory agent for cancer therapy[1]. PD-1[1]
NP-12 displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions [1].NP-12 rescues the proliferation in the mouse splenocyte assay system, with average EC50 values of 17 nM and 16.6 nM against rmPD-L1 and rmPD-L2 respectively[1].NP-12 is also able to significantly rescue recombinant human PD-L1 and PD-L2 mediated inhibition of in vitro human PBMC proliferation, with average EC50 values of 63.3 nM and 44.1 nM against PD-L1 and PD-L2 respectively[1].
[1]. Sasikumar PG, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091.
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *